Year 2018, Volume 8, Issue 3, Pages 207 - 210 2018-09-28

Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml

Eren Altun [1] , Gülay Turan [2] , Figen Aslan [3] , Serpil Paksoy [4]

29 169

Objectives: Prostate specific antigen (PSA) is the most commonly used marker

for prostate cancer. PSA-based screening has reduced disease-specific mortality.

However, PSA is not specific for prostate cancer, but is specific for prostate tissue and

increases in benign conditions.

Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or less

were evaluated retrospectively with 636 patients who underwent prostate sampling

because of the suspicion of prostate cancer.

Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below

1.5 ng / ml of PSA. Our results suggest that a significant number of cancers were

detected below 1.5 ng / ml of PSA.

Conclusion: A significant number of prostate cancers are found below 1.5 ng / ml

PSA. The lack of a PSA value that we can say without prostate cancer leads to the

need for a low cost and reliable marker.

Prostate cancer; Prostate Specific Antigen; Prostate Biopsy
  • Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, et al. Early Stage Prostate Cancer An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016; 96: 116-120.
Primary Language en
Journal Section Articles
Authors

Author: Eren Altun

Author: Gülay Turan

Author: Figen Aslan

Author: Serpil Paksoy

Dates

Publication Date: September 28, 2018

Bibtex @research article { marusbed465494, journal = {Clinical and Experimental Health Sciences}, issn = {}, eissn = {2459-1459}, address = {Marmara University}, year = {2018}, volume = {8}, pages = {207 - 210}, doi = {}, title = {Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml}, key = {cite}, author = {Altun, Eren and Turan, Gülay and Aslan, Figen and Paksoy, Serpil} }
APA Altun, E , Turan, G , Aslan, F , Paksoy, S . (2018). Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml. Clinical and Experimental Health Sciences, 8 (3), 207-210. Retrieved from http://dergipark.org.tr/marusbed/issue/39474/465494
MLA Altun, E , Turan, G , Aslan, F , Paksoy, S . "Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml". Clinical and Experimental Health Sciences 8 (2018): 207-210 <http://dergipark.org.tr/marusbed/issue/39474/465494>
Chicago Altun, E , Turan, G , Aslan, F , Paksoy, S . "Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml". Clinical and Experimental Health Sciences 8 (2018): 207-210
RIS TY - JOUR T1 - Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml AU - Eren Altun , Gülay Turan , Figen Aslan , Serpil Paksoy Y1 - 2018 PY - 2018 N1 - DO - T2 - Clinical and Experimental Health Sciences JF - Journal JO - JOR SP - 207 EP - 210 VL - 8 IS - 3 SN - -2459-1459 M3 - UR - Y2 - 2019 ER -
EndNote %0 Clinical and Experimental Health Sciences Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml %A Eren Altun , Gülay Turan , Figen Aslan , Serpil Paksoy %T Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml %D 2018 %J Clinical and Experimental Health Sciences %P -2459-1459 %V 8 %N 3 %R %U
ISNAD Altun, Eren , Turan, Gülay , Aslan, Figen , Paksoy, Serpil . "Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml". Clinical and Experimental Health Sciences 8 / 3 (September 2018): 207-210.
AMA Altun E , Turan G , Aslan F , Paksoy S . Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml. Clinical and Experimental Health Sciences. 2018; 8(3): 207-210.
Vancouver Altun E , Turan G , Aslan F , Paksoy S . Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml. Clinical and Experimental Health Sciences. 2018; 8(3): 210-207.